You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

10 Results
Guidelines and Advice
Guidelines and Advice
Status: Archived
ID: DIBrCa
Apr 2012
Drug
Other Name(s): Sprycel®
Feb 2025
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Other Name(s): Inqovi®
Feb 2025
Drug
Other Name(s): Jemperli
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    degarelix
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
Feb 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Adjuvant
Updated
Apr 2025